Evidence map›Paper›PMID 40229875›Full record

ArticleJournal of nanobiotechnology2025

Translational selenium nanomedicine synergizes with nab-paclitaxel to enhance antitumor effects in esophageal squamous cell cancer via selenoprotein N-mediated ER stress.

Haoyang Huang, Shaowei Liu, Ligeng Xu, Hengrui Liang, Zihao Wu, Tianfeng Chen, Jinlin Wang, Jun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haoyang HuangDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Shaowei LiuDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Ligeng XuDepartment of Chemistry, Jinan University, Guangzhou, 510632, China.
Hengrui LiangDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Zihao WuDepartment of Chemistry, Jinan University, Guangzhou, 510632, China.
Tianfeng ChenDepartment of Chemistry, Jinan University, Guangzhou, 510632, China. tchentf@jnu.edu.cn.
Jinlin WangPulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. wangjinlin@gird.cn.
Jun LiuDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. ljxwkgy@126.com.

Funding

National Key R&D Program of China 2023YFC3402800National Key Research and Development Program of the Ministry of Science and Technology of China 2022YFB4702604The National Natural Science Foundation for Distinguished Young Scholars 82225025
6 · The paper itself

Abstract

Though prescribed as first-line drugs for esophageal squamous cell cancer (ESCC) therapy, the antitumor efficacy of Nab-Paclitaxel (Nab-PTX) is still unsatisfactory owing to the limitation on the dosage and therapy duration of Nab-PTX caused by adverse effects. Inspired by the very essential role of Selenoprotein N (SelN) in mediating the calcium homeostasis and the associated redox homeostasis in cells, herein, in this essay, we screened the inhibition effect of selenium-containing drugs in different forms on ESCC cell line. Investigation on KYSE-150 cells demonstrated that Nab-PTX in combination with low dosage of LNT-SeNPs may synergistically improve its antitumor efficacy on ESCC cells through promoting the cellular apoptosis. Proteomics analysis uncovered the core synergistic mechanism of LNT-SeNPs on Nab-PTX was significantly dependent on the endoplasmic reticulum (ER) stress induced by SelN-mediated Ca

Indexed as

AlbuminsAntineoplastic AgentsEndoplasmic Reticulum StressEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaPaclitaxelSeleniumSelenoproteinsAnimalsApoptosisCell Line, TumorDrug SynergismHumansMiceMice, Inbred BALB CMice, Nude130-nm albumin-bound paclitaxelAlbuminsAntineoplastic AgentsPaclitaxelSeleniumSelenoproteinsER stressEsophageal squamous cell cancerSelenium nanoparticlesSelenoprotein

Identifiers

PMID40229875
PMCPMC11998242

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.